Epratuzumab in non-Hodgkin's lymphomas

Current Treatment Options in Oncology
Richard R FurmanJohn P Leonard

Abstract

Non-Hodgkin's lymphomas (NHL) are a diverse group of malignancies that result, in addition to their treatments, in significant morbidity and mortality in the population. The identification of more effective and better tolerated treatments is of vital importance. Immunotherapy using monoclonal antibodies directed against the CD20 protein has had a profound impact on the management of patients with B-cell NHL. Additional antigen targets are being aggressively investigated. The targeting of lymphoma cells with monoclonal antibodies offers a treatment with a potentially noncross-resistant mechanism of action and a more favorable toxicity profile compared to chemotherapy. Epratuzumab (humanized LL2) is a humanized immunoglobulin G1 monoclonal antibody directed against the CD22 protein in which expression is restricted to mature B cells. Because of important differences in the characteristics of CD22 compared to CD20, epratuzumab may become an important component of future therapies for NHL.

References

Jan 1, 1991·The Journal of Experimental Medicine·G L WilsonJ H Kehrl
Jan 1, 1997·Annual Review of Immunology·T F TedderJ H Kehrl
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Mar 13, 2001·Leukemia·D M O'Gorman, T G Cotter
Jul 28, 2001·The New England Journal of Medicine·R J KreitmanI Pastan
Jun 19, 2002·Blood·Simona RonchettiPier Paolo Pandolfi
Jun 19, 2002·Blood·Andreas GoldammerMartin Haas
Feb 27, 2003·Immunology·Nicholas R Pritchard, Kenneth G C Smith
Jul 3, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P LeonardDavid M Goldenberg
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John P LeonardDavid M Goldenberg

❮ Previous
Next ❯

Citations

Aug 22, 2006·Expert Opinion on Biological Therapy·Serge D Steinfeld, Pierre Youinou
Feb 4, 2010·Experimental and Molecular Pathology·Kristin LoomisAnu Puri
Nov 6, 2008·Rheumatic Diseases Clinics of North America·Manuel Ramos-CasalsPilar Brito Zerón
Feb 3, 2007·Arthritis and Rheumatism·Manuel Ramos-CasalsUNKNOWN SS-HCV Study Group
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P LeonardDavid M Goldenberg
Oct 4, 2016·Therapeutic Advances in Hematology·Nikolaos Papadantonakis, Anjali S Advani
Oct 4, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kyle J BednarMatthew S Macauley
Jan 1, 2014·International Scholarly Research Notices·Monika PodhoreckaJohannes Pawlowski

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
John P LeonardDavid M Goldenberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
John P LeonardDavid M Goldenberg
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
John P LeonardDavid M Goldenberg
© 2022 Meta ULC. All rights reserved